Modality
Vaccine
MOA
AHRant
Target
Cl18.2
Pathway
Innate Imm
PBC
Development Pipeline
Preclinical
~Sep 2014
→ ~Dec 2015
Phase 1
~Mar 2016
→ ~Jun 2017
Phase 2
Sep 2017
→ Jul 2031
Phase 2Current
NCT06198900
2,544 pts·PBC
2017-09→2031-07·Completed
NCT05354301
1,907 pts·PBC
2018-04→2031-02·Active
4,451 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2031-02-084.9y awayPh3 Readout· PBC
2031-07-235.3y awayPh3 Readout· PBC
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Complet…
P2/3
Active
Catalysts
Ph3 Readout
2031-02-08 · 4.9y away
PBC
Ph3 Readout
2031-07-23 · 5.3y away
PBC
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06198900 | Phase 2/3 | PBC | Completed | 2544 | ACR20 |
| NCT05354301 | Phase 2/3 | PBC | Active | 1907 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 |